Design and development of HDAC11-specific chemical inhibitors for disease treatments

项目摘要 这项重新提交的提案旨在阐明组蛋白脱乙酰酶HDAC11在此类疾病中的作用。 作为多发性硬化症(MS)，并建立HDAC11抑制作为潜在有效的新治疗策略 对于包括MS在内的疾病来说，MS是一种慢性、免疫介导的中枢神经系统脱髓鞘疾病 系统。像许多自身免疫性疾病一样，它目前还没有已知的治疗方法，目前可以治疗的药物 治疗这种疾病只是在早期才有效，而且伴随着许多不良反应。这种病 多发性硬化的发病机制尚不清楚，对慢性进行性多发性硬化尚无有效的靶向治疗方法。 我们的初步研究表明，HDAC11基因的缺失可以改善MS小鼠模型的临床症状。 与此同时，我们发现了一种新的HDAC11酶活性，其效率是其 脱乙酰酶活性。这一新的活动使我们能够开始揭示HDAC11的生理底物，它 进而将有助于揭示HDAC11的S作用的生物学机制。这项研究的目标之一是 为了研究这种新发现的酶活性是如何支持免疫调节功能的 从这些研究中获得的知识将有助于进一步了解MS的发病机制 并开发更好的治疗方法。因为一种新的HDAC11活性的发现使我们能够 首次开发HDAC11特异性抑制剂，主要目标是进一步改进这些抑制剂 并在我们建立的小鼠模型中测试它们是否可以用于治疗多发性硬化症等疾病。我们的 多学科团队拥有使该项目成功所需的所有方面的专业知识。总体而言， 拟议中的这一应用研究不仅将使我们更好地理解HDAC11的S在健康中的作用 和疾病，但也可能导致治疗慢性进展性疾病的第一个靶向治疗原型 多发性硬化症，可能还有其他疾病。

Project Summary This resubmission proposal aims to elucidate the role of a histone deacetylase, HDAC11, in diseases such as multiple sclerosis (MS), and to establish HDAC11 inhibition as a potentially effective new treatment strategy for diseases including MS. MS is a chronic, immune-mediated demyelinating disease of the central nervous system. Like many autoimmune disorders, it presently has no known cure, and current drugs available for managing this disease are only effective early on and are accompanied by many adverse effects. The disease mechanism of MS remains unclear, and no effective targeted therapy is available for chronic progressive MS. Our preliminary studies show that deletion of HDAC11 ameliorates clinical symptoms in a mouse model of MS. In parallel, we discovered a novel HDAC11 enzymatic activity that is >10,000-fold more efficient than its deacetylase activity. This novel activity allows us to begin to uncover physiologic substrates of HDAC11, which in turn will help to uncover the biological mechanisms of HDAC11’s actions. One of the goals of this research is to investigate how this newly discovered enzymatic activity underlies the immune-regulatory function of HDAC11 in MS. Knowledge gained from these studies will help to further understand the disease mechanism of MS and to develop better therapeutics. Because the discovery of a novel HDAC11 activity has enabled us to develop, for the first time, HDAC11-specific inhibitors, the chief objective is to further improve these inhibitors and test whether they can be used to treat diseases such as MS in our established mouse models. Our multidisciplinary team has expertise in all aspects needed to make this project successful. Overall, the proposed studies in this application will not only yield a better understanding of HDAC11’s function in health and diseases, but may also result in a first prototype targeted therapy for the treatment of chronic progressive MS, and possibly other diseases as well.